ArticleJournal of immunology research2019
Relationship between the Degrees of Itch and Serum Lipocalin-2 Levels in Patients with Psoriasis.
Article in Journal of immunology research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Association of Serum Lipocalin-2 Concentrations with Psoriasis and Psoriatic Arthritis: An Updated Meta-Analysis.Disease markers · 2019Pooled it
- Misregulation of T-box transcription factors drives BNP-NPR1 signalling underlying chronic itch.Nature communications · 2026Article
- Environmental toxicant ochratoxin A induces psoriasis based on network toxicology machine learning and molecular docking analyses.Scientific reports · 2026Article
- Emerging roles of lipocalin-2-mediated neuroimmune interactions in chronic pain and itch.Frontiers in pharmacology · 2026Review
- Evaluation of Plasma Opioid and Serum Lipocalin-2 Levels in Pruritic Skin Diseases.Juntendo medical journal · 2025Article
- Is there still a place for neutrophil gelatinase-associated lipocalin to serve as a biomarker in psoriasis?Postepy dermatologii i alergologii · 2024Article
- Predicting Factors and Clinical Characteristics of Pruritus in Psoriasis: A Cross-Sectional Survey.Life (Basel, Switzerland) · 2024Article
- Periostin C-Terminal Is Intrinsically Disordered and Interacts with 143 Proteins in an In Vitro Epidermal Model of Atopic Dermatitis.Biochemistry · 2023Article
- Gene Ontology Analysis Highlights Biological Processes Influencing Responsiveness to Biological Therapy in Psoriasis.Pharmaceutics · 2023Article
- Human umbilical cord mesenchymal stem cell treatment alleviates symptoms in an atopic dermatitis-like mouse model.Stem cell research & therapy · 2023Article
- Inflammatory Skin Disease Causes Anxiety Symptoms Leading to an Irreversible Course.International journal of molecular sciences · 2023Article
- Increased plasma lipocalin-2 levels correlate with disease severity and may be a marker of acute inflammatory response in patients with psoriasis.Dermatology reports · 2022Article
- Critical Players and Therapeutic Targets in Chronic Itch.International journal of molecular sciences · 2022Review
- Lipocalin 2 Participates in the Epidermal Differentiation and Inflammatory Processes of Psoriasis.Journal of inflammation research · 2022Review
- Impact of Chronic Inflammation in Psoriasis on Bone Metabolism.Frontiers in immunology · 2022Review
- Article
- Characteristics of Pruritus in Various Clinical Variants of Psoriasis: Results of the Multinational, Multicenter, Cross-Sectional Study.Life (Basel, Switzerland) · 2021Article
- Network analysis of potential risk genes for psoriasis.Hereditas · 2021Article
- Molecular Aspects of Pruritus Pathogenesis in Psoriasis.International journal of molecular sciences · 2021Review
- Adipokines in the Skin and in Dermatological Diseases.International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLipocalin-2 (LCN2), a protein secreted mainly by activated neutrophils, has been associated with neurodegeneration, obesity, and inflammatory responses. Serum LCN2 concentration has been reported elevated in patients with psoriasis, but lower in patients with atopic dermatitis (AD). Spinal astrocyte-derived LCN2 was found to be involved in enhancement of itch in a mouse model of AD. However, the relationship between LCN2 and itch in patients with psoriasis has not been determined
methodsSerum LCN2 concentrations were measured by enzyme-linked immunosorbent assays (ELISA) in patients with psoriasis and AD and in healthy controls. The degree of itch was assessed using a visual analog scale (VAS), and disease severity was determined by measuring psoriasis area and severity index (PASI) and scoring atopic dermatitis (SCORAD). Correlations among serum LCN2 level, VAS, PASI, and SCORAD were analyzed statistically. We further examined the serum LCN levels in psoriasis patients before and after biological treatment.
resultsSerum LCN2 concentrations were significantly higher in patients with psoriasis and AD than those in healthy controls. In patients with psoriasis, serum LCN2 concentrations were significantly correlated with VAS, but not with PASI. In contrast, serum LCN2 concentrations did not correlate with VAS or SCORAD in patients with AD. Serum LCN2 levels in psoriasis patients significantly decreased after the biological treatment along with improvement of VAS.
conclusionSerum LCN2 concentration is associated with the degree of itch in patients with psoriasis, suggesting that serum LCN2 may be a useful clinical marker for itch in psoriasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.